|
R&D Project
|
Cell Lines
|
Host System
|
Preferred Model
|
Key Endpoints
|
| BRAF mutation early efficacy screening |
A375, SK-MEL-28, Colo829, WM793 |
BALB/c nude, NOD-SCID, NSG |
BRAF-mutant subcutaneous CDX |
TGI, RTV, terminal tumor weight, pERK, pMEK, Ki67, apoptosis, PK/PD. |
| BRAF/MEK resistance and withdrawal rechallenge |
A375-resistant lines, Colo829-resistant lines, long-term dosing-induced models |
BALB/c nude, NOD-SCID, NSG |
BRAF CDX with long-term dosing or resistant derivatives, orthotopic confirmation when needed |
Time to relapse, pERK recovery, bypass pathway, RTV regrowth, resistance markers. |
| NRAS/NF1 background programs |
SK-MEL-2, SK-MEL-30, WM1366 |
BALB/c nude, NOD-SCID, NSG |
Molecularly matched subcutaneous CDX, orthotopic or metastasis model for confirmation when needed |
TGI, pERK, pAKT, MEK/ERK/PI3K pathway, cell cycle, apoptosis. |
| High-invasion / local invasion research |
A2058, WM266-4, A375-luc |
BALB/c nude, NOD-SCID, NSG |
High-invasion CDX, skin orthotopic model for confirmation |
TGI, local invasion, EMT, MMP, local pathology, survival. |
| Skin local microenvironment and lymphatic dissemination |
A375-luc, A2058-luc, WM266-4-luc, B16-F10-luc, YUMM/YUMMER |
BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice |
Skin orthotopic model |
Orthotopic burden, local invasion, lymph node metastasis, IVIS, survival, immune infiltration. |
| Lung metastasis colonization research |
B16-F10-luc, A375-luc, A2058-luc |
C57BL/6 immunocompetent mice; NSG, NOD-SCID |
Tail vein experimental lung metastasis model |
Lung nodule count, lung weight, IVIS, lung histopathology, survival. |
| Orthotopic spontaneous lung metastasis / postoperative metastasis relapse |
B16-F10-luc, A2058-luc, YUMM/YUMMER |
C57BL/6 immunocompetent mice; NSG, NOD-SCID |
Skin orthotopic model with long-term observation or post-resection follow-up |
Orthotopic burden, post-resection relapse, lung metastasis, survival, time to relapse. |
| Brain metastasis and BBB scenario |
A2058-Br, A375-Br, B16-F10-Br, high-invasion brain metastasis derivatives |
BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice |
Left ventricle / carotid artery brain metastasis or intracranial inoculation model |
MRI, BLI, brain metastatic lesions, survival, neurobehavior, brain edema, brain tissue exposure. |
| Uveal melanoma liver metastasis |
OMM1, 92.1, Mel290, liver metastasis derivatives |
BALB/c nude, NOD-SCID, NSG |
Liver metastasis model, with intraocular orthotopic linkage when needed |
Liver nodule count, liver weight, IVIS, liver pathology, survival, GNAQ/GNA11-related pathway |
| Immune checkpoint / combination immunotherapy |
B16-F10, B16-F1, YUMM1.7, YUMMER1.7 |
C57BL/6 immunocompetent mice |
Syngeneic immunocompetent model, orthotopic preferred |
TGI/IVIS, CD8/Treg, myeloid cells, PD-L1, IFN-γ, Granzyme B, survival |
| STING / oncolytic virus / radiotherapy combination |
B16-F10-luc, YUMM1.7, YUMMER1.7 |
C57BL/6 immunocompetent mice |
Syngeneic subcutaneous or orthotopic model |
Orthotopic burden, immune infiltration, cytokines, necrosis, abscopal effect, survival. |
| TCE / CAR-T/NK / human immune-dependent therapies |
A375, SK-MEL-28, A2058, WM266-4 and others |
huPBMC or huHSC-reconstituted NSG/NOG mice |
Humanized immune model |
hCD45, hCD3, hCD8, hNK, T cell activation, cytokines, xGvHD/CRS risk. |
| Postoperative relapse / MRD clearance |
B16-F10-luc, YUMM/YUMMER, A2058-luc |
C57BL/6 immunocompetent mice; NSG, NOD-SCID |
Skin orthotopic model with post-resection relapse observation |
Local relapse, lung/brain metastasis, survival, MRD clearance, immune infiltration. |